Kimberly Brown-Gullatt, MD
Family Medicine · Columbus, GANPI 1902836000
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations.
Across 120 payments — averaging $27.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$574
- Bayer$319
- AbbVie$283
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$266
- Lilly USA, LLC$236
- Pfizer$183
- plus $1K from 23 others
Across 15 payments — averaging $2636.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vivus LLC$21K
- Eli Lilly$18K
What the payments were for
- Food & beverage$3,19298%
- Education$562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $574 |
| Bayer | 17 | $319 |
| AbbVie(2 entities) | 17 | $283 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $266 |
| Lilly USA, LLC | 12 | $236 |
| Pfizer | 11 | $183 |
| Novo Nordisk | 10 | $154 |
| Sanofi-aventis U.S. LLC | 2 | $139 |
| Novartis | 4 | $133 |
| GSK | 2 | $122 |
| Sobi, Inc | 1 | $120 |
| Seagen Inc. | 1 | $119 |
| Merck | 6 | $89 |
| Regeneron Healthcare Solutions, Inc. | 1 | $80 |
| Boehringer Ingelheim | 4 | $67 |
| Vertex | 3 | $65 |
| Corcept Therapeutics | 1 | $56 |
| Exact Sciences | 2 | $33 |
| Abbott | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Cardiovascular Systems Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Valeritas, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Global Blood Therapeutics, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,248 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 229 | $279,680 |
| JanuviaSitagliptin Phosphate | 112 | $150,792 |
| OzempicSemaglutide | 74 | $114,387 |
| TrulicityDulaglutide | 63 | $102,048 |
| JardianceEmpagliflozin | 61 | $98,684 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $60,614 |
| TradjentaLinagliptin | 42 | $59,462 |
| RybelsusSemaglutide | 30 | $55,848 |
| EliquisApixaban | 33 | $51,424 |
| LinzessLinaclotide | 22 | $28,062 |
| VraylarCariprazine Hcl | 17 | $27,249 |
| XareltoRivaroxaban | 17 | $26,050 |
| InvokanaCanagliflozin | 15 | $22,241 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $21,350 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $20,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $574 | $288,376252 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $67 | $178,814121 claims |
| MerckJanuvia, Janumet | $89 | $172,142128 claims |
| Novo NordiskOzempic, Rybelsus | $154 | $170,235104 claims |
| Lilly USA, LLCTrulicity | $236 | $102,04863 claims |
| GSKTrelegy Ellipta, Shingrix | $122 | $64,72659 claims |
| AbbVieLinzess, Vraylar, Restasis Multidose | $283 | $62,59650 claims |
| PfizerEliquis | $183 | $51,42433 claims |
| Johnson & JohnsonXarelto, Invokana | $11 | $48,29132 claims |
| NovartisEntresto | $133 | $13,01717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Columbus
- Jeffrey KingsleyColumbus$404K
- Bantwal BaligaColumbus$115K
- Joseph LewisColumbus$18K
- Mark SextonColumbus$18K
- Jason BermanColumbus$16K
- Debbie HaginsSavannah$279K
- Yolanda WadeTyrone$233K
- Julian HutchinsWarrenton$222K
- Nadine Halliburton-FosterCumming$219K
- Contessa MetcalfeAtlanta$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.